市場調查報告書

原發性硬化性膽管炎(PSC):市場規模,佔有率,趨勢,預測 ∼2023年

Primary Sclerosing Cholangitis Market - Size, Share, Trends, and Forecast to 2023

出版商 Coherent Market Insights 商品編碼 785772
出版日期 內容資訊 英文 134 Pages
商品交期: 2-3個工作天內
價格
原發性硬化性膽管炎(PSC):市場規模,佔有率,趨勢,預測 ∼2023年 Primary Sclerosing Cholangitis Market - Size, Share, Trends, and Forecast to 2023
出版日期: 2018年07月16日內容資訊: 英文 134 Pages
簡介

原發性硬化性膽管炎(PSC)市場成長的主要原因有為了闡明原發性硬化性膽管炎(PSC)的機制與危險因子的研究開發熱絡。

本報告提供全球原發性硬化性膽管炎(PSC)市場調查,提供市場概要,醫藥品·各地區的市場規模的變化與預測,市場成長要素及阻礙因素,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場概要

  • 報告概要
  • 摘要整理

第3章 市場動態,開發平台(管線),PEST分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • PEST分析
  • 開發平台分析
  • 支援PSC和研究的配合措施
  • 第三階段臨床試驗的中止理由
  • 面臨的課題:罕見疾病用候補藥
  • 流行病學

第4章 全球原發性硬化性膽管炎(PSC)市場:各類醫藥品

  • 簡介
  • BTT1023
  • GS-9674
  • NGM282
  • OCA
  • Cenicriviroc
  • LUM001
  • DUR928
  • norUDCA
  • HTD 1801
  • IDN-7314
  • STP705

第5章 全球原發性硬化性膽管炎(PSC)市場:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第6章 競爭環境

  • 企業簡介
    • Acorda Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • NGM Biopharmaceuticals, Inc.
    • Intercept Pharmaceuticals, Inc.
    • Dr. Falk Pharma GmbH
    • Allergan Plc.
    • Shire Plc.
    • Durect Corporation
    • Conatus Pharmaceuticals, Inc.
    • Sirnaomics, Inc.
    • Shenzhen HighTide Biopharmaceutical Ltd.
  • 分析師的意見

第7章 章節

  • 參考文獻
  • 調查方法
  • 關於Coherent Market Insights
目錄

Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations. The drug segment will provide quick snapshot about the clinical phase of the study, study outcomes, estimated launch date, and the upcoming drug molecules. Moreover, the report entails information regarding the major events taking place in the global market, thereby gaining insights about drug approvals, merger agreements, and acquisitions undertaken by the manufacturing companies. Also, incidence and prevalence of PSC and its associated conditions at regional as well as global level are provided in the report, thereby indicating the total number of addressable patient pool in the respective regions and market opportunity for the same.

Market Dynamics

Major factors that are expected to augment growth of the primary sclerosing cholangitis market include increasing number of organizations focusing on clinical innovation and scientific progress on understanding the mechanisms and risk factors for primary sclerosing cholangitis (PSC). For instance, the International PSC study group (IPSCSG), founded in 2010, aims to coordinate PSC research projects between leading institutions worldwide, thereby allowing feasible translational research and advancing efficient research. Also, increasing number of clinical and preclinical trials conducted by the research universities and pharmaceuticals companies is expected to favor market growth over the forecast period.

However, failure of drug candidates to provide desired study outcomes and the withdrawal of late phase clinical trials of potential drug molecules are factors hindering the market growth.

Key features of the study:

This report provides in-depth analysis of primary sclerosing cholangitis market and provides pipeline analysis for the same

It elucidates potential opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global primary sclerosing cholangitis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans

Key companies covered as a part of this study include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

The global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the primary sclerosing cholangitis market

Detailed Segmentation:

  • Global Primary Sclerosing Cholangitis Market, By Drug:
  • BTT1023
  • GS-9674
  • NGM282
  • OCA
  • Cenicriviroc
  • LUM001
  • DUR928
  • norUDCA
  • HTD1801
  • IDN-7314
  • STP705
  • Global Primary Sclerosing Cholangitis Market, By Region:
  • North America
  • Regional Overview
  • Latin America
  • Regional Overview
  • Europe
  • Regional Overview
  • Asia Pacific
  • Regional Overview
  • Middle East
  • Regional Overview
  • Africa
  • Regional Overview
  • Company Profiles
  • Acorda Therapeutics, Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Gilead Sciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Dr. Falk Pharma GmbH
  • Allergan Plc.
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceuticals Ltd.
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Overview
    • Optimistic, Likely and Pessimistic Overview

3. Market Dynamics, Pipeline, and PEST Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • PEST Analysis
  • Pipeline Analysis
  • Initiatives Focusing On PSC Support And Research
  • Reason For Phase 3 Drug Withdrawal
  • Challenges Faced by Orphan Drug Candidates
  • Epidemiology

4. Global Primary Sclerosing Cholangitis Market, By Drug

  • Introduction
  • BTT1023
    • Research Details
  • GS-9674
    • Research Details
  • NGM282
    • Research Details
  • OCA
    • Research Details
  • Cenicriviroc
    • Research Details
  • LUM001
    • Research Details
  • DUR928
    • Research Details
  • norUDCA
    • Research Details
  • HTD1801
    • Research Details
  • IDN-7314
    • Research Details
  • STP705
    • Research Details

5. Global Primary Sclerosing Cholangitis Market, By Region

  • Introduction
  • North America
    • Regional Overview
  • Latin America
    • Regional Overview
  • Europe
    • Regional Overview
  • Asia Pacific
    • Regional Overview
  • Middle East
    • Regional Overview
  • Africa
    • Regional Overview

6. Competitive Landscape

  • Company Profiles
    • Acorda Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Gilead Sciences, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • NGM Biopharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Intercept Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dr. Falk Pharma GmbH
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Allergan Plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Shire Plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Durect Corporation
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Conatus Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sirnaomics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Shenzhen HighTide Biopharmaceutical Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

7. Section

  • References
  • Research Methodology
  • About us and Sales Contact